Immunotherapy plus chemo shows promise for Tough-to-Treat nasopharyngeal cancer

NCT ID NCT03930498

Ongoing Disease control Sponsor: Sun Yat-sen University Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This phase II trial is testing whether combining an immunotherapy drug (PD-1 antibody) with standard chemotherapy and radiation can help people whose nasopharyngeal cancer has come back after initial treatment. The study includes 68 participants with high-risk recurrent cancer that cannot be surgically removed. Researchers are measuring survival, tumor response, side effects, and quality of life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PD-1 antibody (toripalimab) plus chemotherapy (cisplatin and gemcitabine) and radiation therapy
What this could lead to: If successful, this combination could offer a new treatment option for people with recurrent nasopharyngeal cancer that is hard to treat.
What could go wrong: This is a small, early-phase trial with no comparison group, so results may not be definitive. Side effects from the combination therapy could be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT NASOPHARYNGEAL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

nasopharyngeal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECURRENT NASOPHARYNGEAL CARCINOMA

Contacts and locations

Locations

Sun Yat-sen University Cancer Center

Guangzhou, Guangdong, 510060, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.